Analyses of Transcriptomics Cell Signalling for Pre-Screening Applications in the Integrated Approach for Testing and Assessment of Non-Genotoxic Carcinogens

Int J Mol Sci. 2022 Oct 22;23(21):12718. doi: 10.3390/ijms232112718.

Abstract

With recent rapid advancement of methodological tools, mechanistic understanding of biological processes leading to carcinogenesis is expanding. New approach methodologies such as transcriptomics can inform on non-genotoxic mechanisms of chemical carcinogens and can be developed for regulatory applications. The Organisation for the Economic Cooperation and Development (OECD) expert group developing an Integrated Approach to the Testing and Assessment (IATA) of Non-Genotoxic Carcinogens (NGTxC) is reviewing the possible assays to be integrated therein. In this context, we review the application of transcriptomics approaches suitable for pre-screening gene expression changes associated with phenotypic alterations that underlie the carcinogenic processes for subsequent prioritisation of downstream test methods appropriate to specific key events of non-genotoxic carcinogenesis. Using case studies, we evaluate the potential of gene expression analyses especially in relation to breast cancer, to identify the most relevant approaches that could be utilised as (pre-) screening tools, for example Gene Set Enrichment Analysis (GSEA). We also consider how to address the challenges to integrate gene panels and transcriptomic assays into the IATA, highlighting the pivotal omics markers identified for assay measurement in the IATA key events of inflammation, immune response, mitogenic signalling and cell injury.

Keywords: carcinogenicity; gene expression; integrated approaches to testing and assessment (IATA); non-genotoxic carcinogen(s) (NGTxC(s)); organisation for economic co-operation and development (OECD); transcriptomics.

Publication types

  • Review

MeSH terms

  • Biological Assay
  • Carcinogenesis
  • Carcinogenicity Tests / methods
  • Carcinogens* / toxicity
  • Humans
  • Transcriptome*

Substances

  • Carcinogens

Grants and funding

M.L. received financial support from the Dutch Ministry of Health, Welfare and Sport; M.P. received financial support from the Austrian Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology, Department V/5—Chemicals Policy and Biocides. All other authors were funded by their parent institutions. This research received no external funding.